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Very elderly NSCLC patients above 75 years: Response to 
chemotherapy and improvement in Quality of Life is achievable 
to the same extent as for younger patients during platinum-based 
doublet chemotherapy
Sørensen, Jens B.; Bæksgaard, Lene; Henriksen, Anders; Hasselbalch, 
Benedicte; Perell, Katharina; Dandanell, Jette 
Dept. Oncology, Finsen Centre/National University Hospital, Copenha-
gen, Denmark
Background: Elderly patients with Non-Small Cell Lung Cancer 
(NSCLC) are rarely included in clinical trials; hence the knowledge on 
their potential beneﬁt from chemotherapy is limited. The purpose of 
this study was to illuminate to what extend very elderly patients above 
75 years responded to chemotherapy and whether the palliative treat-
ment actually improved their Quality of Life (QOL).
Methods: Patients with non-resectable NSCLC were consecutively 
entered from 05/2001-08/2006. Treatment until 12/2003 was cisplatin 
100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 i.v. weekly for 4-6 
courses (CiV), and from 01/2004 onward treatment was carboplatin 
AUC 5 (Calvert formula) every 3 weeks and vinorelbine 25 mg/m2 i.v. 
day one and 60-80 mg/m2 orally day 8 in each course for a total of 4-6 
courses (CaV) dependent of response. Patients had no upper age limit, 
normal renal-, hepatic-, and bone marrow function and performance 
status 0-2. Patients gave written informed consent. EORTC QoL ques-
tionnaire C-30 and LC-13was used.
Results: A total of 101 patients were treated, with 15 being older than 
75 years (CiV 9 pts; CaV 6 pts), 41 being 70-75 years (CiV 23 pts; CaV 
18 pts), and 45 being 36-69 years. Median age for patients above 70 
years were for CiV 74 years (range 70-84) and for CaV 74 years (range 
70-78), respectively. The characteristics for these 56 pts above 70 years 
were males 39%, performance status 0, 1, and 2 in 27%, 59%, and 
14%, and stages IIIA, IIIB without pleural effusion, IIIB with pleural 
effusion, and IV in 14%, 13%, 11%, and 63%, respectively. Partial and 
complete responses were obtained in 8 out of 15 pts > 75 years (re-
sponse rate (RR) 53%; 95% conﬁdence limits 27-79%)(CiV RR 56%; 
CaV RR 50%), in 14 out of 41 pts aged 70-75 (RR 34%, 95% conﬁ-
dence limits 20-51%)(CiV 35%; Cav 33%), and in 38% of younger 
pts (95% c.l. 24-53%) (not signiﬁcant). Improvement or stabilisation 
of QoL issues were at follows for pts >75 years, 70-75 years, and <70 
years: Dyspnoea 57%, 62%, 69%; pain 71%, 74%, 76%; cough 79%, 
82%, 93%; and global QoL 86%, 77%, 73%, respectively. Increased or 
stabilised G-I side effects were 93%, 77%, 36%; and other side effects 
36%, 53%, 20%, respectively.
Conclusions: The change for achieving a response to chemotherapy is 
similar for very elderly pts >75 years, patients aged 70-75, and younger 
patients. Also the beneﬁts with respect to improvement of lung cancer 
related symptoms and global QoL seems to be similar. However, this 
is based on very few patients in this very elderly patient group. Even 
though they fulﬁl the same inclusion criteria as their younger counter-
part they clearly represent a highly selected group in good condition 
with preserved organ function and are a much smaller fraction of the 
lung cancer population in their age group than the younger patients. 
Thus, even though beneﬁt from chemotherapy is possible to achieve, 
careful patient selection is of outmost importance in this geriatric 
population.
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Lung cancer patients admitted to the micu: improved outcome
Soubani, Ayman O.1 Adam, Abdulgadir K.2 Wazniak, Antoinette1 
1 Karmanos Cancer Center, Detroit, MI, USA 2 Wayne State University, 
Detroit, MI, USA 
Objective: To assess the outcome of lung cancer patients who were 
admitted to a medical ICU (MICU), and to identify the measurable 
predictors of their MICU outcome.
Design: Retrospective chart review study.
Setting: MICUs of a university afﬁliated medical center
Patients: Adult lung cancer patients admitted to the MICU between 
January 1998 and October 2005.
Measurements and Main Results: 139 lung cancer patients included 
during the study period. The mean age (±SD) at MICU admission was 
64.2 ± 10.2years (men 48%, women 52%). 96 patients (69%) had non-
small cell lung cancer, 18 patients (13%) had small cell lung cancer, 
and one patient had mesothelioma. 108 patients (78%) survived their 
MICU stay, and 83 patients (60%) were discharged alive from the 
hospital. 68 patients (49%) required mechanical ventilation (MV), 42 
patients (62%) mechanically ventilated patients survived their MICU 
stay. The independent predictors of poor outcome during the MICU 
stay were the need for MV, APACHE III and SAPS III scores, the use 
of vasopressors, positive blood cultures, high serum lactate, two or 
more organ system failure, the need for ACLS. On multivariate analysis 
only the need for vasopressors and the presence of two or more organ 
systems failure predicted poor MICU outcome.
Conclusion: The study showed the MICU outcome of lung cancer 
patients is better than previously reported. Intensive care and MV 
should not be considered futile care in this patient population. While 
there were no absolute predictors of mortality, the need for vasopres-
sors and the presence of two or more organ systems failure predicted 
poor MICU.
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Regional Cancer Centre (RCC) and Community Hospital (CH) 
Collaboration: A New Paradigm For Lung Cancer Service 
Organization? 
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Background: Lung cancer is the leading cause of cancer death in 
Canada. Contemporary healthcare systems have been criticized for 
being too fragmented and the organization of services inﬂuences the 
accessibility, quality and outcome of medical care. Within Ontario 
Canada, service centralization has been reported as being associated 
with uneven access and waiting times for some cancer patients have 
been deemed excessive. Multidisciplinary (MD) lung cancer Tumor 
Boards (TB) may increase resection rate, chemotherapy and radiothera-
py use and perhaps survival. They also provide a forum for integrating 
evidence into clinical practice. This abstract describes a novel collab-
orative paradigm for the organization of thoracic oncology services de-
veloped by colleagues from the Toronto-Sunnybrook Regional Cancer 
